Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology.
about
Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents.Cardiotoxicity screening: a review of rapid-throughput in vitro approaches.What can nanosafety learn from drug development? The feasibility of "safety by design".Automated electrophysiology makes the pace for cardiac ion channel safety screening.TRPA1: Acrolein meets its target.
P2860
Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology.
@en
Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology.
@nl
type
label
Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology.
@en
Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology.
@nl
prefLabel
Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology.
@en
Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology.
@nl
P2860
P356
P1476
Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology.
@en
P2093
Clemens Möller
P2860
P304
P356
10.1586/ECP.10.24
P407
P577
2010-05-01T00:00:00Z